Singapore markets open in 3 hours 8 minutes
  • Straits Times Index

    3,188.50
    -9.58 (-0.30%)
     
  • S&P 500

    4,549.78
    +13.59 (+0.30%)
     
  • Dow

    35,603.08
    -6.26 (-0.02%)
     
  • Nasdaq

    15,215.70
    +94.02 (+0.62%)
     
  • BTC-USD

    62,456.90
    -3,259.94 (-4.96%)
     
  • CMC Crypto 200

    1,490.38
    -44.27 (-2.88%)
     
  • FTSE 100

    7,190.30
    -32.80 (-0.45%)
     
  • Gold

    1,783.70
    -1.20 (-0.07%)
     
  • Crude Oil

    82.62
    +0.12 (+0.15%)
     
  • 10-Yr Bond

    1.6760
    +0.0400 (+2.44%)
     
  • Nikkei

    28,708.58
    -546.97 (-1.87%)
     
  • Hang Seng

    26,017.53
    -118.49 (-0.45%)
     
  • FTSE Bursa Malaysia

    1,591.62
    -14.70 (-0.92%)
     
  • Jakarta Composite Index

    6,632.97
    -23.03 (-0.35%)
     
  • PSE Index

    7,311.72
    +14.64 (+0.20%)
     

Stoke Therapeutics to Present at the Cantor Global Healthcare Virtual Conference

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

BEDFORD, Mass., September 22, 2021--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines, today announced that Chief Medical Officer Barry Ticho, M.D., Ph.D., will present at the Cantor Global Healthcare Virtual Conference on Tuesday, September 28, 2021, at 4:00 p.m. ET.

A live audio webcast of the presentation, which will be conducted in fireside chat format, will be available on the Investors & Media section of Stoke’s website at https://investor.stoketherapeutics.com/. A replay of the webcast will be available for 30 days following the fireside chat.

About Stoke Therapeutics
Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines. Using the Company’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. The Company’s first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. Dravet syndrome is one of many diseases caused by a haploinsufficiency, in which a loss of ~50% of normal protein levels leads to disease. The Company is pursuing treatment for a second haploinsufficient disease, autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. Stoke’s initial focus is haploinsufficiencies and diseases of the central nervous system and the eye, although proof of concept has been demonstrated in other organs, tissues, and systems, supporting the Company’s belief in the broad potential for its proprietary approach. Stoke is headquartered in Bedford, Massachusetts with offices in Cambridge, Massachusetts. For more information, visit https://www.stoketherapeutics.com/ or follow the Company on Twitter at @StokeTx.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210922005948/en/

Contacts

Stoke Investor Contact:
Eric Rojas
Vice President, Investor Relations
IR@stoketherapeutics.com
617-312-2754

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting